Novel vascular targeting/disrupting agents: Combretastatin A4 phosphate and related compounds

Current Oncology Reports

Volumn 7, Issue 2, 2005, Pages 90-95

  Cooney, Matthew M ^a   Ortiz, Jose ^a   Bukowski, Ronald M ^a   Remick, Scot C ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTIARRHYTHMIC AGENT; COMBRETASTATIN; COMBRETASTATIN A4 PHOSPHATE; COMBRETASTATIN B1; N ACETYLCOLCHINOL PHOSPHATE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANOREXIA; ANXIETY DISORDER; AREA UNDER THE CURVE; ATAXIA; BONE MARROW SUPPRESSION; CANCER PAIN; CLINICAL TRIAL; COLON CANCER; CONFUSION; CONSTIPATION; CYTOTOXICITY; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; DYSPNEA; ECG ABNORMALITY; FATIGUE; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOXIA; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROPATHY; QT PROLONGATION; REVIEW; SLURRED SPEECH; SOLID TUMOR; SYNCOPE; TORSADE DES POINTES; TREMOR; TUMOR VASCULARIZATION; URINE INCONTINENCE; VISUAL DISORDER; VOMITING;

EID: 16844367677     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0033-x     Document Type: Review

References (35)

1. Konerding MA, Miodonski AJ, Lametschwandtner A: Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc 1995, 9:1233-1244.
2. Konerding MA, van Ackern C, Fait E, et al.: Morphological aspects of tumor angiogenesis and microcirculation. In Blood Perfusion and Microenvironment of Human Tumors. Edited by Molls M, Vaupel P. Berlin: Springer-Verlag; 2002:5-17.
3. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49:6449-6465.
4. Brown JM, Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998, 58:1408-1416.
5. Siemann DW: Vascular targeting agents. Horizons in Cancer Therapy from Bench to Bedside 2002, 3:4-15.
6. Tannok IF: The relationship between cell proliferation and the vascular system in transplanted mouse mammary tumor. Br J Cancer 1968, 22:258-273.
7. Giaccia AJ: Hypoxic stress proteins: survival of the fittest. Semin Radiat Oncol 1996, 6:46-58.
8. Graeber T, Osmanian C, Jacks T, et al.: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996, 379:88-91.
9. Young SD, Marshall RS, Hill RP: Hypoxia induces DNA over-replication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A 1988, 85:9533-9537.
10. Hill RP: Tumor progression: potential role of unstable genomic changes. Cancer Metastasis Rev 1990, 9:137-147.
11. Veenendaal LM, Jin H, Ran S, et al.: In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 2002, 99:7866-7871.
12. Chang SM, Reuter VE, Heston WDW, et al.: Five different anti-prostate specific membrane antigens (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999, 59:3192-3198.
13. Pettit GR, Cragg GM, Herald DL, et al.: Isolation and structure of combretastatin. Can J Chem 1982, 60: 374-6.
14. Dark GG, Hill SA, Prise VE, et al.: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997, 57:1829-1834.
15. Dark GG, Hill S, Prise A, et al.: Combretastatin A-4, and agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997, 57:1829-1834.
16. Tozer GM, Prise VE, Wilson J, et al.: Combretastatin A-4 phosphate as tumor vascular-targeting agent early effects in tumors and normal tissues. Cancer Res 1999, 59:1626-1634.
17. Dowlati A, Robertson K, Cooney MM, et al.: Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002, 62: 408-3416.
18. Cooney MM, Radivoyevitch T, Dowlat A, et al.: Cardiovascular safety profile of combretastatin A4 phosphate (CA4P) in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004, 10:96-100.
19. Guatteo E, Faravelli L, Verotta L, et al.: A novel K+ channel blocker isolated from 'hiccup nut' toxin. NeuroReport 1996, 7:2575-2579.
20. Anderson HL, Yap JT, Miller MP, et al.: Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A-4 phosphate. J Clin Oncol 2003, 21:2823-2830.
21. Rustin GJS, Galbraith SM, Anderson H, et al.: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003, 21:2815-2822.
22. Stevenson JP, Rosen M, Sun W, et al.: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003, 21:4428-4438.
23. Bilenker JH, Stevenson JP, Rosen MA, et al.: Phase Ib trial of combretastatin A-4 (CA4P) in combination with carboplatin in patients with advanced cancer [abstract]. Proc ASCO 2002, 21: 22.
24. Scurr M, Judson I, Brock C, et al.: Assessment of metabolism, excretion and pharmacokinetics of a single dose of [14C]-ZD6126 in patients with solid malignant tumors [abstract]. Proc ASCO 2004, 23:3083.
25. DelProposto Z, LoRusso PM, Latif Z, Morton P: MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature [abstract]. Proc ASCO 2002, 21:440.
26. Gadgeel SM, LoRusso PM, Wozniak AJ, Wheeler C: A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors [abstract]. Proc ASCO 2002, 21: 38.
27. Ohsumi K, Hatanaka T, Nakagawa R, et al.: Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins. Anticancer Drug Des 1999, 14:539-548.
28. Lejune P, Hodge TG, Vrignaud P, et al.: In vivo antitumor activity and tumor necrosis induced by AVE8062, a tumor vasculature targeting agent [abstract]. AACR Proc 2002, 43: 56.
29. Tolcher AW, Forero L, Celio P, et al.: Phase I pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days [abstract]. Proc ASCO 2003, 22:834.
30. Zhou S, Kestell P, Baguley BC, Paxton JW: 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest New Drugs 2002, 20: 81-295.
31. Galbraith SM, Rustin GJS, Lodge MA, et al.: Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002, 20:3826-3840.
32. Jameson MB, Thompson PI, Baguley BC, et al.: Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003, 88:1844-1850.
33. Remick SC, Greskovich J, Cooney MM, et al.: CWRU 3302: Phase II trial of combined modality combretastatin A-4 phosphate (CA4P)-based therapy for patients with newly diagnosed anaplastic thyroid cancer. Case Comprehensive Clinical Trial database, Version 3.1, June 16, 2004.
34. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004, 10:415-427.
35. Fox SB, Gatter KC, Bicknell R, et al.: Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 1993, 53:4161-4163.